Inventor · disambiguated record
Alexander Levitzki
Also filed as: LEVITZKI ALEXANDER
41 granted patents·15 pending applications·1,777 citations·filing 1991–2023
98Inventor score
Files withYISSUM RES DEV CO15TARGIMMUNE THERAPEUTICS AG7SUGEN INC5REUVENI HADAS4HADASIT MED RES SERVICE2
Top patents by PatentIndex Score
56 records- 0199US5302606AStyryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1991·Granted Apr 12, 1994·284 cites·12 claims
- 0299US5217999AStyryl compounds which inhibit EGF receptor protein tyrosine kinaseYISSUM RES DEV CO·Filed 1992·Granted Jun 8, 1993·302 cites·21 claims
- 0398US5773476AMethods and compositions for inhibiting cell proliferative disordersSUGEN INC·Filed 1995·Granted Jun 30, 1998·153 cites·17 claims
- 0498US5712395ACompounds for the treatment of disorders related to vasculogenesis and/or angiogenesisYISSUM RES DEV CO·Filed 1995·Granted Jan 27, 1998·118 cites·1 claims
- 0597US5763441ACompounds for the treatment of disorders related to vasculogenesis and/or angiogenesisSUGEN INC·Filed 1995·Granted Jun 9, 1998·111 cites·4 claims
- 0697US5196446ACertain indole compounds which inhibit EGF receptor tyrosine kinaseYISSUM RES DEV CO·Filed 1991·Granted Mar 23, 1993·101 cites·15 claims
- 0795US5792771AQuinazoline compounds and compositions thereof for the treatment of diseaseSUGEN INC·Filed 1995·Granted Aug 11, 1998·155 cites·12 claims
- 0890US6596878B2Methods and compositions for inhibiting cell proliferative disordersYISSUM RES & DEV COMPANY OF TH·Filed 2001·Granted Jul 22, 2003·26 cites·11 claims
- 0990US6562319B2Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapyYISSUM RES DEV CO·Filed 2001·Granted May 13, 2003·89 cites·40 claims
- 1090US5656655AStyryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinaseRHONE-POULENC INC·Filed 1995·Granted Aug 12, 1997·50 cites·10 claims
- 1188US5981569ASubstituted phenylacrylonitrile compounds and compositions thereof for the treatment of diseaseYISSUM RES DEV CO·Filed 1995·Granted Nov 9, 1999·86 cites·16 claims
- 1288US5932580APDGF receptor kinase inhibitory compounds their preparation and compositionsYISSUM RES DEV CO·Filed 1997·Granted Aug 3, 1999·95 cites·15 claims
- 1388US5849742ACompounds for the treament of disorders related to vasculogenesis and/or angiogenesisSUGEN INC·Filed 1997·Granted Dec 15, 1998·28 cites·14 claims
- 1481US9006406B2EGFR-homing double-stranded RNA vector for systemic cancer treatmentLEVITZKI ALEXANDER·Filed 2009·Granted Apr 14, 2015·6 cites·2 claims
- 1581US7745468B2Compounds for treatment of cell proliferative diseasesUNIV TEXAS·Filed 2004·Granted Jun 29, 2010·12 cites·23 claims
- 1681US6126917AEpidermal growth factor receptor binding compounds for positron emission tomographyHADASIT MED RES SERVICE·Filed 1999·Granted Oct 3, 2000·62 cites·9 claims
- 1776US5677329AStyryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit EGF receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1995·Granted Oct 14, 1997·15 cites·16 claims
- 1874US6673798B2PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including sameYISSUM RES DEV CO·Filed 2001·Granted Jan 6, 2004·10 cites·31 claims
- 1973US8058309B2Protein kinase modulators and therapeutic uses thereofREUVENI HADAS·Filed 2007·Granted Nov 15, 2011·6 cites·14 claims
- 2072US9096499B2Compounds for treatment of cell proliferative diseasesUNIV TEXAS·Filed 2014·Granted Aug 4, 2015·1 cites·10 claims
- 2172US7217737B2Method and compositions for inhibiting cell proliferative disordersSUGEN INC·Filed 2003·Granted May 15, 2007·3 cites·15 claims
- 2271US8648102B2Compounds for treatment of cell proliferative diseasesPRIEBE WALDEMAR·Filed 2012·Granted Feb 11, 2014·1 cites·12 claims
- 2371US8119827B2Compounds for treatment of cell proliferative diseasesPRIEBE WALDEMAR·Filed 2010·Granted Feb 21, 2012·1 cites·16 claims
- 2470US9073880B22-(2-phenylethenyl) 1,3-benzodiazepine derivatives useful for the treatment of cancerREUVENI HADAS·Filed 2011·Granted Jul 7, 2015·1 cites·18 claims
- 2569US8637575B2Modulators of protein kinase signalingREUVENI HADAS·Filed 2009·Granted Jan 28, 2014·1 cites·20 claims
- 2669US8372818B2Targeted double stranded RNA mediated cell killingYISSUM RES DEV CO·Filed 2011·Granted Feb 12, 2013·1 cites·11 claims
- 2767US2024033364A1Castration resistant prostate cancerTARGIMMUNE THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 2866US8461166B2Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinaseMISHANI EYAL·Filed 2007·Granted Jun 11, 2013·1 cites·37 claims
- 2965US7927792B2Targeted double stranded RNA mediated cell killingYISSUM RES DEV CO·Filed 2003·Granted Apr 19, 2011·2 cites·11 claims
- 3065US6949565B2Protein kinase inhibitorsYISSUM RES DEV CO·Filed 2001·Granted Sep 27, 2005·3 cites·21 claims
- 3163US2022213158A1CHIMERIC PROTEINS FOR TARGETING dsRNATARGIMMUNE THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 3261US11912747B2Chimeric proteins for targeting dsRNATARGIMMUNE THERAPEUTICS AG·Filed 2016·Granted Feb 27, 2024·0 cites·20 claims
- 3361US11679160B2Castration resistant prostate cancerTARGIMMUNE THERAPEUTICS AG·Filed 2018·Granted Jun 20, 2023·0 cites·20 claims
- 3460US6358954B1PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including sameYISSUM RES DEV CO·Filed 1999·Granted Mar 19, 2002·16 cites·20 claims
- 3559US8044032B2Selective killing of cells by activation of double-stranded RNA dependent protein kinase-PKRYISSUM RES DEV CO·Filed 2006·Granted Oct 25, 2011·0 cites·13 claims
- 3659US7172749B2Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapyHADASIT MED RES SERVICE·Filed 2003·Granted Feb 6, 2007·1 cites·135 claims
- 3756US6426366B1Pharmaceutical compositions comprising tyrphostinsNOTOX LTD·Filed 1997·Granted Jul 30, 2002·19 cites·13 claims
- 3855US9770454B2IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseasesYISSUM RES DEV CO·Filed 2014·Granted Sep 26, 2017·0 cites·12 claims
- 3954US10188659B2IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseasesYISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD·Filed 2017·Granted Jan 29, 2019·0 cites·11 claims
- 4053US11230580B2Chimeric proteins for targeting dsRNATARGIMMUNE THERAPEUTICS AG·Filed 2018·Granted Jan 25, 2022·0 cites·20 claims
- 4151USRE38761EStyryl compounds which inhibit EGF receptor protein tyrosine kinaseYISSUM RES DEV CO·Filed 1994·Granted Jul 19, 2005·13 cites·32 claims
- 4249US2003153083A1Selective killing of cells by activation of double-stranded rna dependent protein kniase-pkrFiled 2001·Application pending·0 cites
- 4348US2004132725A1PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including sameFiled 2003·Application pending·0 cites
- 4448US2020407453A1A recombinant protein comprising a double stranded rna binding domainTARGIMMUNE THERAPEUTICS AG·Filed 2019·Application pending·0 cites
- 4547US2009156507A1Cell permeable conjugates of peptides for inhibition of protein kinasesCUREGENICS LTD·Filed 2008·Application pending·0 cites
- 4646US2022175814A1Immunotherapy for the treatment of cancerTARGIMMUNE THERAPEUTICS AG·Filed 2020·Application pending·0 cites
- 4745US5990277ASemipeptoid farnesyl protein transferase inhibitors and analogs thereofYISSUM RES DEV CO·Filed 1996·Granted Nov 23, 1999·4 cites·10 claims
- 4845US2004214186A1Method for identifying constitutively active mutants of mitogen activated protein kinase (mapk) and uses thereofFiled 2002·Application pending·0 cites
- 4943US2005143430A1Catechol bioisosteresFiled 2004·Application pending·0 cites
- 5042US2007078092A1Cell permeable conjugates of peptides for inhibition of protein kinasesLIVNAH NURIT·Filed 2005·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →